Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Liabilities and Shareholders Equity (2016 - 2025)

CorMedix has reported Liabilities and Shareholders Equity over the past 15 years, most recently at $826.1 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $826.1 million for Q4 2025, up 595.14% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (up 514.3% YoY), and the annual figure for FY2025 was $826.1 million, up 595.14%.
  • Liabilities and Shareholders Equity reached $826.1 million in Q4 2025 per CRMD's latest filing, up from $750.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $826.1 million in Q4 2025 and bottomed at $57.0 million in Q2 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $76.5 million (2021), compared with a mean of $157.9 million.
  • The largest annual shift saw Liabilities and Shareholders Equity fell 22.94% in 2022 before it soared 867.78% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $68.9 million in 2021, then fell by 10.02% to $62.0 million in 2022, then surged by 32.27% to $82.1 million in 2023, then surged by 44.83% to $118.8 million in 2024, then skyrocketed by 595.14% to $826.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CRMD at $826.1 million in Q4 2025, $750.9 million in Q3 2025, and $252.6 million in Q2 2025.